1. Search Result
Search Result
Isoforms Recommended: STAT1
Results for "

STAT-1

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Screening Libraries

1

Inhibitory Antibodies

4

Natural
Products

2

Recombinant Proteins

6

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0069
    Fludarabine
    Maximum Cited Publications
    39 Publications Verification

    F-ara-A; NSC 118218

    Nucleoside Antimetabolite/Analog DNA/RNA Synthesis STAT Apoptosis Cancer
    Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes [1] .
    Fludarabine
  • HY-W013523
    2-NP
    2 Publications Verification

    STAT Cancer
    2-NP is a selective enhancer of STAT1 transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells [1].
    2-NP
  • HY-RS13886

    Small Interfering RNA (siRNA) Others

    STAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STAT1 Human Pre-designed siRNA Set A
    STAT1 Human Pre-designed siRNA Set A
  • HY-122891

    PI3K CXCR STAT Cancer
    SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity [1] .
    SB02024
  • HY-N8107

    Others Others
    Matairesinol monoglucoside, a lignan compound, exhibits low activity on IFN-γ/STAT1 and IL-6/STAT3 signaling pathways with inhibition ratio of 5.8% and 7.0%, respectively [1].
    Matairesinol monoglucoside
  • HY-W035137

    5,15-DPP

    STAT Cancer
    5,15-Diphenylporphyrin (5,15-DPP) is a selective STAT3-SH2 antagonist (IC50s of 0.28 µM and 10 µM for STAT3 and STAT1, respectively) [1].
    5,15-Diphenylporphyrin
  • HY-115594

    STAT Apoptosis Cancer
    Erasin is a potent Erlotinib (HY-50896)-resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis [1].
    Erasin
  • HY-161060

    RIP kinase Inflammation/Immunology
    Zharp1-211 is a potent inhibitor of RIPK1 kinase. Zharp1-211 significantly reduces the expression of JAK/STAT1-mediated chemokines and MHC class II molecules in intestinal epithelial cells [1].
    Zharp<em>1</em>-211
  • HY-114495
    Caerulomycin A
    1 Publications Verification

    Cerulomycin; Caerulomycin

    Fungal Antibiotic Infection Inflammation/Immunology
    Caerulomycin A (Cerulomycin; Caerulomycin), an antifungal compound, induces generation of T cells, enhances TGF-β-Smad3 protein signaling via suppressing interferon-γ-induced STAT1 signaling. Antifungal and antibiotic activity, and used in autoimmune diseases [1].
    Caerulomycin A
  • HY-119347
    Cirsilineol
    1 Publications Verification

    IFNAR STAT Inflammation/Immunology Cancer
    Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 + T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice [1].
    Cirsilineol
  • HY-146666

    Apoptosis STAT Cancer
    STAT3-IN-9 is a potent STAT3 inhibitor. STAT3-IN-9 inhibits the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). STAT3-IN-9 induces apoptosis and cell cycle arrest at the G2/M phase [1].
    <em>STAT</em>3-IN-9
  • HY-107429
    Abrocitinib
    4 Publications Verification

    PF-04965842

    JAK Inflammation/Immunology
    Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease [1].
    Abrocitinib
  • HY-149974

    Apoptosis CDK Cancer
    CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces Apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity [1].
    CDK8-IN-13
  • HY-149007
    STAT3-IN-11
    1 Publications Verification

    STAT Apoptosis Cancer
    STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers [1].
    <em>STAT</em>3-IN-11
  • HY-P99666

    IFNAR Infection
    Albinterferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Albinterferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function [1].
    Interferon alfa
  • HY-149209

    CDK STAT Early 2 Factor (E2F) Cancer
    LL-K8-22 is a potent, selective and durable CDK8-cyclin C dual degrader, with DC50 values of 2.52 and 2.64 μM, respectively. LL-K8-22 also suppresses STAT1 Ser 727 phosphorylation. LL-K8-22 inhibits E2F- and MYC-driven carcinogenic transcriptional programs. LL-K8-22 can be used for triplenegative breast cancer (TNBC) research [1].
    LL-K8-22
  • HY-111388A
    SEL120-34A monohydrochloride
    5 Publications Verification

    CDK Cancer
    SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726 [1]. Has anti-tumor activity [1].
    SEL120-34A monohydrochloride
  • HY-13571A
    Beclometasone dipropionate
    3 Publications Verification

    Beclomethasone dipropionate

    Glucocorticoid Receptor Reactive Oxygen Species NO Synthase Inflammation/Immunology Endocrinology
    Beclometasone dipropionate, the proagent of Beclometasone, is an orally active and potent glucocorticoid recepter agonist. Beclometasone dipropionate acts via a glucocorticoid receptor and suppresses inflammation and hyperproliferation. Beclometasone dipropionate can be used for asthma [1] .
    Beclometasone dipropionate
  • HY-13571B

    Glucocorticoid Receptor Reactive Oxygen Species NO Synthase Inflammation/Immunology Cancer
    Beclometasone dipropionate monohydrate, the proagent of Beclometasone, is an orally active and potent glucocorticoid recepter agonist. Beclometasone dipropionate monohydrate acts via a glucocorticoid receptor and suppresses inflammation and hyperproliferation. Beclometasone dipropionate monohydrate can be used for asthma [1] .
    Beclometasone dipropionate monohydrate
  • HY-N3548

    NF-κB Inflammation/Immunology
    Catalpalactone has anti-inflammatory effect. Catalpalactone inhibits LPS-induced NO production and iNOS expression in RAW264.7 cells, and also inhibits IRF3, NF-κB, and IFN-β/STAT-1 activation. Catalpalactone also inhibits dopamine biosynthesis by reducing tyrosine hydroxylase (TH) and aromatic-l-amino acid decarboxylase (AADC) activities [1] .
    Catalpalactone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: